Allelic variants of full-length VAR2CSA, the placental malaria vaccine candidate, differ in antigenicity and receptor binding affinity

Commun Biol. 2021 Nov 19;4(1):1309. doi: 10.1038/s42003-021-02787-7.

Abstract

Plasmodium falciparum-infected erythrocytes (IE) sequester in the placenta via surface protein VAR2CSA, which binds chondroitin sulfate A (CSA) expressed on the syncytiotrophoblast surface, causing placental malaria (PM) and severe adverse outcomes in mothers and their offspring. VAR2CSA belongs to the PfEMP1 variant surface antigen family; PfEMP1 proteins mediate IE adhesion and facilitate parasite immunoevasion through antigenic variation. Here we produced deglycosylated (native-like) and glycosylated versions of seven recombinant full-length VAR2CSA ectodomains and compared them for antigenicity and adhesiveness. All VAR2CSA recombinants bound CSA with nanomolar affinity, and plasma from Malian pregnant women demonstrated antigen-specific reactivity that increased with gravidity and trimester. However, allelic and glycosylation variants differed in their affinity to CSA and their serum reactivities. Deglycosylated proteins (native-like) showed higher CSA affinity than glycosylated proteins for all variants except NF54. Further, the gravidity-related increase in serum VAR2CSA reactivity (correlates with acquisition of protective immunity) was absent with the deglycosylated form of atypical M200101 VAR2CSA with an extended C-terminal region. Our findings indicate significant inter-allelic differences in adhesion and seroreactivity that may contribute to the heterogeneity of clinical presentations, which could have implications for vaccine design.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Antigens, Protozoan / immunology*
  • Female
  • Humans
  • Immunogenicity, Vaccine*
  • Malaria Vaccines / immunology*
  • Malaria, Falciparum / prevention & control
  • Placenta / immunology
  • Plasmodium falciparum / immunology*
  • Pregnancy
  • Protein Binding

Substances

  • Antigens, Protozoan
  • Malaria Vaccines
  • VAR2CSA protein, Plasmodium falciparum